Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1128/JCM.02596-20 http://scihub22266oqcxt.onion/10.1128/JCM.02596-20 33574119!8091860!33574119     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Clin+Microbiol 2021 ; 59 (5): ä Nephropedia Template TP {{tp|p=33574119|t=2021. Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories |pdf=|usr=}}{{33574119}} gab.com Text Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories JO: J Clin Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=33574119 #FOAvip Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to support clinical diagnosis and epidemiological investigations. Recently, assays for large-scale detection of total antibodies (Ab), immunoglobulin G (IgG), and IgM against SARS-CoV-2 antigens have been developed, but there are limited data on the diagnostic accuracy of these assays. This study was a Danish national collaboration and evaluated 15 commercial and one in-house anti-SARS-CoV-2 assays in 16 laboratories. Sensitivity was evaluated using 150 samples from individuals with asymptomatic, mild, or moderate COVID-19, nonhospitalized or hospitalized, confirmed by nucleic acid amplification tests (NAAT); samples were collected 13 to 73 days either from symptom onset or from positive NAAT (patients without symptoms). Specificity and cross-reactivity were evaluated in samples collected prior to the SARS-CoV-2 epidemic from >586 blood donors and patients with autoimmune diseases, cytomegalovirus or Epstein-Barr virus infections, and acute viral infections. A specificity of >/=99% was achieved by all total-Ab and IgG assays except one, DiaSorin Liaison XL IgG (97.2%). Sensitivities in descending order were Wantai ELISA total Ab (96.7%), CUH-NOVO in-house ELISA total Ab (96.0%), Ortho Vitros total Ab (95.3%), YHLO iFlash IgG (94.0%), Ortho Vitros IgG (93.3%), Siemens Atellica total Ab (93.2%), Roche Elecsys total Ab (92.7%), Abbott Architect IgG (90.0%), Abbott Alinity IgG (median 88.0%), DiaSorin Liaison XL IgG (median 84.6%), Siemens Vista total Ab (81.0%), Euroimmun/ELISA IgG (78.0%), and Snibe Maglumi IgG (median 78.0%). However, confidence intervals overlapped for several assays. The IgM results were variable, with the Wantai IgM ELISA showing the highest sensitivity (82.7%) and specificity (99%). The rate of seropositivity increased with time from symptom onset and symptom severity. Twit Text FOAVip Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories ????J Clin Microbiol http://www.kidney.de/pget.php?&tw=1&pmid=33574119 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33574119 #FOAvip English Wikipedia <ref>{{Cite pmid|33574119}}</ref> Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical Laboratories #MMPMID33574119 Harritshoj LH; Gybel-Brask M; Afzal S; Kamstrup PR; Jorgensen CS; Thomsen MK; Hilsted L; Friis-Hansen L; Szecsi PB; Pedersen L; Nielsen L; Hansen CB; Garred P; Korsholm TL; Mikkelsen S; Nielsen KO; Moller BK; Hansen AT; Iversen KK; Nielsen PB; Hasselbalch RB; Fogh K; Norsk JB; Kristensen JH; Schonning K; Kirkby NS; Nielsen ACY; Landsy LH; Loftager M; Holm DK; Nilsson AC; Saekmose SG; Grum-Schwensen B; Aagaard B; Jensen TG; Nielsen DM; Ullum H; Dessau RB J Clin Microbiol 2021[Apr]; 59 (5): ä PMID33574119show ga Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are needed to support clinical diagnosis and epidemiological investigations. Recently, assays for large-scale detection of total antibodies (Ab), immunoglobulin G (IgG), and IgM against SARS-CoV-2 antigens have been developed, but there are limited data on the diagnostic accuracy of these assays. This study was a Danish national collaboration and evaluated 15 commercial and one in-house anti-SARS-CoV-2 assays in 16 laboratories. Sensitivity was evaluated using 150 samples from individuals with asymptomatic, mild, or moderate COVID-19, nonhospitalized or hospitalized, confirmed by nucleic acid amplification tests (NAAT); samples were collected 13 to 73 days either from symptom onset or from positive NAAT (patients without symptoms). Specificity and cross-reactivity were evaluated in samples collected prior to the SARS-CoV-2 epidemic from >586 blood donors and patients with autoimmune diseases, cytomegalovirus or Epstein-Barr virus infections, and acute viral infections. A specificity of >/=99% was achieved by all total-Ab and IgG assays except one, DiaSorin Liaison XL IgG (97.2%). Sensitivities in descending order were Wantai ELISA total Ab (96.7%), CUH-NOVO in-house ELISA total Ab (96.0%), Ortho Vitros total Ab (95.3%), YHLO iFlash IgG (94.0%), Ortho Vitros IgG (93.3%), Siemens Atellica total Ab (93.2%), Roche Elecsys total Ab (92.7%), Abbott Architect IgG (90.0%), Abbott Alinity IgG (median 88.0%), DiaSorin Liaison XL IgG (median 84.6%), Siemens Vista total Ab (81.0%), Euroimmun/ELISA IgG (78.0%), and Snibe Maglumi IgG (median 78.0%). However, confidence intervals overlapped for several assays. The IgM results were variable, with the Wantai IgM ELISA showing the highest sensitivity (82.7%) and specificity (99%). The rate of seropositivity increased with time from symptom onset and symptom severity. |*Immunoassay[MESH] |Antibodies, Viral/*isolation & purification[MESH] |COVID-19 Serological Testing/*methods[MESH] |COVID-19/*diagnosis[MESH] |Cytomegalovirus Infections[MESH] |Enzyme-Linked Immunosorbent Assay[MESH] |Epstein-Barr Virus Infections[MESH] |Herpesvirus 4, Human[MESH] |Humans[MESH] |Immunoglobulin G/isolation & purification[MESH] |Immunoglobulin M/isolation & purification[MESH] |Laboratories[MESH] |SARS-CoV-2[MESH]Comparison of 16 Serological SARS-CoV-2 Immunoassays in 16 Clinical La(epmc).pdf DeepDyve Pubget Overpricing